Skip to main content

Sepsis Diagnostics Market Size to Surpass USD 1,603.3 Million by 2030, exhibiting a CAGR of 9.7%

As per the report by Fortune Business Insights, the global Sepsis Diagnostics Market size is projected to reach USD 1,603.3 Million in 2030, at a CAGR of 9.7% during the forecast period, 2023-2030

Sepsis Diagnostics Market

Sepsis Diagnostics Market Forecast 2023-2030
Sepsis Diagnostics Market Forecast 2023-2030

Pune, India, Sept. 12, 2023 (GLOBE NEWSWIRE) — Global Sepsis Diagnostics Market Size was valued at USD 770.4 million in 2022 and is projected to grow USD 1,603.3 million by 2030, exhibiting a CAGR of 9.7% during the forecast period. It is anticipated that various strategic attempts to introduce new products and technical developments will increase global sepsis diagnostics market share.

When the body’s defense against an infection causes harm to its own tissues, it is thought to be experiencing sepsis. Bacterial infection is one of the most typical causes. Moreover, other diseases, such as viral and fungus infections, can cause this illness. The illness progresses through three stages, sepsis, severe sepsis, and septic shock. For example, according to estimations from the World Health Organization (WHO) for 2020, this illness afflicted around 49.0 million people and resulted in 11.0 million fatalities globally in 2017.


Request a Free Sample PDF – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/sepsis-diagnostics-market-107417

This information is provided by Fortune Business Insights™ in its research report titled Sepsis Diagnostics Market, 2023-2030.

Key Industry Development-

  • May 2020: Danaher’s company, Beckman Coulter, Inc., launched the DxH 690T hematology analyzer mid volume analyzer for early diagnosis of sepsis in the U.S.

Key Takeaways –

  • Sepsis Diagnostics Market size in North America was USD 392.8 million in 2022
  • Rising Incidence of Sepsis Globally Contributes to the Market Growth
  • Improvement in Awareness in Emerging Countries to Boost Diagnostic Procedures
  • The reagents & consumables segment is expected to hold a major market share during the projected period.


Discover the Leading Players Featured in the Report-

T2 Biosystems, Inc. (U.S.), Danaher (U.S.), Abbott (U.S.), bioMérieux SA (France), Thermo Fisher Scientific Inc. (U.S.), Luminex Corporation (DiaSorin S.p.A.) (U.S.), BD (Becton, Dickinson, and Company) (U.S.), Bruker (U.S.), Siemens Healthcare GmbH (Germany)


Report Scope & Segmentation:

Report CoverageDetails
Forecast Period2023 to 2030
Forecast Period 2023 to 2030 CAGR9.7%
2030 Value ProjectionUSD 1,603.3 Million
Base Year2022
Sepsis Diagnostics Market Size in 2022USD 770.4 Million
Historical Data2019 to 2021
No. of Pages185
Segments coveredType, Technology, Pathogen and Geography


Browse Complete Report Details- https://www.fortunebusinessinsights.com/sepsis-diagnostics-market-107417


Drivers & Restraints:

Increasing Awareness in Developing Countries to Promote Diagnostic Procedures

A large number of government and non-government organizations are attempting to raise public awareness of this disease. The Global Sepsis Alliance, one of the most well-known groups, has teamed up with several organizations from Latin America and Africa to spread awareness of this disorder. Additionally, the Global Maternal Sepsis Research and Campaign was launched by the World Health Organization (WHO) in collaboration with 52 nations (GLOSS). It seeks to evaluate the impact and treatment of maternal sepsis and increase awareness of this problem among healthcare professionals. As a result, it is projected that a rise in the number of foundations and government organizations’ attempts to raise awareness and support the market will accelerate this expansion.

However, since there is currently no single diagnostic test for this disorder, medical practitioners combine tests with urgent and concerning clinical indications. Throughout the projected period, the burden and expense of the condition will limit the global sepsis diagnostics market growth.


Segmentation:

By Product Type

  • Instruments
  • Reagents & Consumables

By Technology

By Method

  • Conventional
  • Automated

By Test Type

  • Laboratory Tests
  • Point-of-Care Tests

By Pathogen

  • Bacterial
  • Fungal
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others


Regional Insights:

North America Dominates the Market Due to Fast Adoption of Contemporary Diagnostics

In 2022, the North America market was expected to be worth USD 392.8 million. Over the forecast period, the region is anticipated to dominate the global market. Due to the high frequency of this ailment, rapid uptake of modern sepsis diagnostics, and attractive reimbursement rules, the region dominates the market.


Quick Buy – Sepsis Diagnostics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/107417


Competitive Landscape:

Businesses made Significant Sales to Get Competitive Edge

Luminex Corporation, Bruker, T2 Biosystems, Inc., and others are emerging market participants. In addition to focusing on regional development through territory-exclusive distribution agreements, these players have produced significant sales. The market positions of the aforementioned businesses are predicted to improve as a result. For instance, T2 Biosystems, Inc. signed territory-exclusive sales contracts in Norway, Finland, and Turkey in February 2022. T2 Biosystems sold T2Dx Instruments, T2Bacteria, T2Candida, and T2Resistance Panels via these wholesalers in accordance with the contract. Also, it completed a territory-exclusive distribution arrangement in Taiwan, Singapore, and South Korea in November and October 2021. During the projection period, these strategic initiatives are anticipated to increase these players’ market shares.


FAQs

How big is the Sepsis Diagnostics Market?

Sepsis Diagnostics Market size was USD 770.4 Million in 2022. It is expected to reach USD 1,603.3 Million in 2030.

How fast is the Sepsis Diagnostics Market growing?

The Sepsis Diagnostics Market will exhibit a CAGR of 9.7% during the forecast period, 2023-2030.


Related Reports:

Hospital Acquired Infections Treatment Market Size, Share, Revenue Forecast and Opportunities

Infectious Disease Molecular Diagnostics Market Overview, Industry Share and Forecast

Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share, Trends, Growth 2023-2030

Molecular Diagnostics Market Analysis, Global Size and Industry Share Forecast 2023-2030

In-vitro Diagnostics Market Size, Share, Opportunities & Analysis 2023-2030


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.